US20010047128A1 - Method for non-invasive spectrophotometric blood oxygenation monitoring - Google Patents
Method for non-invasive spectrophotometric blood oxygenation monitoring Download PDFInfo
- Publication number
- US20010047128A1 US20010047128A1 US09/845,146 US84514601A US2001047128A1 US 20010047128 A1 US20010047128 A1 US 20010047128A1 US 84514601 A US84514601 A US 84514601A US 2001047128 A1 US2001047128 A1 US 2001047128A1
- Authority
- US
- United States
- Prior art keywords
- wavelength
- light signal
- hbo
- determining
- attenuation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 108
- 239000008280 blood Substances 0.000 title claims abstract description 87
- 210000004369 blood Anatomy 0.000 title claims abstract description 87
- 238000012544 monitoring process Methods 0.000 title claims description 10
- 238000006213 oxygenation reaction Methods 0.000 title description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 74
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 74
- 239000001301 oxygen Substances 0.000 claims abstract description 74
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 claims abstract description 30
- 108010064719 Oxyhemoglobins Proteins 0.000 claims abstract description 27
- 108010002255 deoxyhemoglobin Proteins 0.000 claims abstract description 27
- 230000008859 change Effects 0.000 claims description 12
- 238000002106 pulse oximetry Methods 0.000 claims description 11
- 238000005070 sampling Methods 0.000 claims description 5
- 239000013074 reference sample Substances 0.000 claims description 4
- 238000001320 near-infrared absorption spectroscopy Methods 0.000 claims 12
- 238000000149 argon plasma sintering Methods 0.000 abstract description 9
- 238000002834 transmittance Methods 0.000 abstract description 3
- 210000001519 tissue Anatomy 0.000 description 59
- 238000004497 NIR spectroscopy Methods 0.000 description 46
- 108010054147 Hemoglobins Proteins 0.000 description 11
- 102000001554 Hemoglobins Human genes 0.000 description 11
- 238000005259 measurement Methods 0.000 description 10
- 230000003287 optical effect Effects 0.000 description 8
- 230000000541 pulsatile effect Effects 0.000 description 7
- 239000006096 absorbing agent Substances 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 3
- 210000002565 arteriole Anatomy 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 210000004731 jugular vein Anatomy 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- CVOFKRWYWCSDMA-UHFFFAOYSA-N 2-chloro-n-(2,6-diethylphenyl)-n-(methoxymethyl)acetamide;2,6-dinitro-n,n-dipropyl-4-(trifluoromethyl)aniline Chemical compound CCC1=CC=CC(CC)=C1N(COC)C(=O)CCl.CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O CVOFKRWYWCSDMA-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 230000000287 tissue oxygenation Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 208000007204 Brain death Diseases 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
- G01N21/359—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
- A61B5/14553—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases specially adapted for cerebral tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1495—Calibrating or testing of in-vivo probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/47—Scattering, i.e. diffuse reflection
- G01N21/49—Scattering, i.e. diffuse reflection within a body or fluid
Definitions
- This invention relates to methods for non-invasively determining biological tissue oxygenation in general, and to non-invasive methods utilizing near-infrared spectroscopy (NIRS) techniques in particular.
- NIRS near-infrared spectroscopy
- the molecule that carries the oxygen in the blood is hemoglobin.
- Oxygenated hemoglobin is called oxyhemoglobin (HbO 2 ) and deoxygenated hemoglobin is deoxyhemoglobin (Hb).
- the mammalian cardiovascular system consists of a blood pumping mechanism (the heart), a blood transportation system (blood vessels), and a blood oxygenation system (the lungs). Blood oxygenated by the lungs passes through the heart and is pumped into the arterial vascular system.
- oxygenated arterial blood consists predominately of HbO 2 .
- oxygen carried by hemoglobin is transported to the cells in the tissue, resulting in the release of oxygen molecules (HbO 2 ⁇ Hb).
- HbO 2 ⁇ Hb oxygen molecules
- the capillaries then combine together into venuoles, the beginning of the venous circulatory system. Venuoles then combine into larger blood vessels called veins. The veins further combine and return to the heart, and then venous blood is pumped to the lungs. In the lungs, deoxygenated hemoglobin Hb collects oxygen becoming HbO 2 again and the circulatory process is repeated.
- pulse oximetry determines arterial oxygen saturation (SaO 2 ) of peripheral tissue (i.e. finger, ear, nose) by monitoring pulsatile optical attenuation changes of detected light induced by pulsatile arterial blood volume changes in the arteriolar vascular system.
- SaO 2 arterial oxygen saturation
- the method of pulse oximetry requires pulsatile blood volume changes in order to make a measurement. Since venous blood is not pulsatile, pulse oximetry cannot provide any information about venous blood.
- NIRS Near-infrared spectroscopy
- the NIRS method is based on the principle that light in the near-infrared range (700 to 1,000 nm) can pass easily through skin, bone and other tissues where it encounters hemoglobin located mainly within micro-circulation passages; e.g., capillaries, arterioles, and venuoles.
- Hemoglobin exposed to light in the near infra-red range has specific absorption spectra that varies depending on its oxidation state; i.e., oxyhemoglobin (HbO 2 ) and deoxyhemoglobin (Hb) each act as a distinct chromophore.
- oxyhemoglobin (HbO 2 ) and deoxyhemoglobin (Hb) each act as a distinct chromophore.
- concentration changes of the oxyhemoglobin (HbO 2 ) and deoxyhemoglobin (Hb) can be monitored.
- the ability to continually monitor cerebral oxygenation levels is particularly valuable for those patients subject to a condition in which oxygenation levels in the brain may be compromised, leading to brain damage or death.
- the apparatus used in NIRS analysis typically includes a plurality of light sources, one or more light detectors for detecting reflected or transmitted light, and a processor for processing signals that represent the light emanating from the light source and the light detected by the light detector.
- Light sources such as light emitting diodes (LEDs) or laser diodes that produce light emissions in the wavelength range of 700-1000 nm at an intensity below that which would damage the biological tissue being examined are typically used.
- a photodiode or other light source detector is used to detect light reflected from or passed through the tissue being examined.
- the processor takes the signals from the light sources and the light detector and analyzes those signals in terms of their intensity and wave properties.
- a ⁇ represents the optical attenuation in tissue at a particular wavelength ⁇ (units: optical density or OD); “I o ” represents the incident light intensity (units: W/cm 2 ); “I” represents the detected light intensity; “ ⁇ ⁇ ” represents the wavelength dependent absorption coefficient of the chromophore (units: OD * cm ⁇ 1 * ⁇ M ⁇ 1 ); “C” represents the concentration of chromophore (units: ⁇ M); “d” represents the light source to detector (optode) separation distance (units: cm); “B ⁇ ” represents the wavelength dependent light scattering differential pathlength factor (unitless); and “G” represents light attenuation due to scattering within tissue (units: OD).
- NIRS algorithms that are designed to calculate the relative change in concentration of more than one chromophore use a multivariate form of Equation 2 or 3.
- ⁇ HbO 2 oxyhemoglobin
- ⁇ Hb deoxyhemoglobin
- concentration of the HbO 2 and Hb within the examined tissue is determined in ⁇ moles per liter of tissue ( ⁇ M).
- NIRS examined brain tissue consists of blood comprising from about 60 to 80% venous to about 20 to 40% arterial blood. Blood samples from catheters placed in venous drainage sites such as the internal jugular vein, jugular bulb, or sagittal sinus-have been used to evaluate NIRS measurements.
- NIRS interrogated tissue consists of a mixed vascular bed with a venous-to-arterial ratio of about 2:1 as determined from multiple linear regression analysis of sagittal sinus oxygen saturation (SSSO 2 ) and carotid artery oxygen saturation (SaO 2 ) in comparison to NIRS measured ⁇ Hb and ⁇ HbO 2 .
- SSSO 2 sagittal sinus oxygen saturation
- SaO 2 carotid artery oxygen saturation
- SmvO 2 mixed venous/arterial oxygen saturation
- SvO 2 represents venous oxygen saturation
- SaO 2 represents arterial oxygen saturation
- the parameters Kv and Ka may have constant values, or they may be a function of SvO 2 and SaO 2 .
- Determined oxygen saturation from the internal jugular vein (SijvO 2 ), jugular bulb (SjbO 2 ), or sagittal sinus (SssO 2 ) can be used to represent SvO 2 .
- Equation 4 the value of each term in Equation 4 is empirically determined, typically by discretely sampling or continuously monitoring and subsequently evaluating patient arterial and venous blood from tissue that the NIRS sensor is examining, and using regression analysis to determine the relative contributions of venous and arterial blood independent of the NIRS examination.
- an object of the present invention to provide a method for non-invasively determining the total level of blood oxygen saturation within biological tissue.
- a method and apparatus for non-invasively determining the blood oxygen saturation level within a subject's tissue utilizes a near infrared spectrophotometric (NIRS) sensor capable of transmitting a light signal into the tissue of a subject and sensing the light signal once it has passed through the tissue via transmittance or reflectance.
- the method includes the step of determining attenuation of the light signal as the sum of: (i) attenuation attributable to deoxyhemoglobin; (ii) attenuation attributable to oxyhemoglobin; and (iii) attenuation attributable to light scattering within the subject's tissue.
- NIRS near infrared spectrophotometric
- the present method also makes it possible to account for attenuation attributable to fixed or constant light absorbing biological tissue components, and attenuation attributable to variable characteristics of the sensor.
- differential attenuation as a function of wavelength
- the attenuation attributable to tissue light scattering characteristics, fixed light absorbing components, and measuring apparatus characteristics are mathematically cancelled out or minimized relative to the attenuation attributable to deoxyhemoglobin, and attenuation attributable to oxyhemoglobin.
- each of the parameters must be measured or calibrated out. Since direct measurement is difficult, calibration to empirically determined data combined with data developed using the NIRS sensor is performed by using regression techniques. The empirically determined data is collected at or about the same time the data is developed with the NIRS sensor. Once the calibration parameters associated with attenuation attributable to tissue light scattering characteristics, fixed light absorbing components, and measuring apparatus characteristics have been determined, the NIRS sensor can be calibrated.
- the calibrated sensor can then be used to accurately and non-invasively determine the total oxygen saturation level in the original subject tissue or other subject tissue.
- the separation distance (“d”) between the light source to the light detector is known or is determinable, and if the value of “B”, which represents the wavelength dependent light scattering differential pathlength factor, is known, then the total amount of concentrations of deoxyhemoglobin (Hb) and oxyhemoglobin (HbO 2 ) within the examined tissue can be determined using the present method and apparatus.
- the calibrated sensor can be used subsequently to calibrate similar sensors without having to invasively produce a blood sample.
- the present method and apparatus enables a non-invasive determination of the blood oxygen saturation level within tissue.
- an operator can create reference values by sensing a light signal or other reference medium using the calibrated sensor.
- the operator can then calibrate an uncalibrated sensor by sensing the same light signal or reference medium, and subsequently adjusting the uncalibrated sensor into agreement with the calibrated sensor.
- a reference sensor is created, other similar sensors can be calibrated without the need for invasive procedure.
- Those advantages include: 1) a practical non-invasive method and apparatus for determining oxygen saturation within tissue that can be used to determine the total blood oxygen saturation within tissue as opposed to a change in blood oxygen saturation; 2) a calibration method that accounts for light attenuation due to scattering within tissue (G), fixed tissue absorbers (F), and measuring apparatus variability (N); and 3) a practical non-invasive method and apparatus for determining oxygen saturation within tissue that can distinguish between the contribution of oxygen saturation attributable to venous blood and that saturation attributable to arterial blood.
- aspects of the above-described methodology are combined with pulse oximetry techniques to provide a non-invasive method of distinguishing between blood oxygen saturation within tissue that is attributable to venous blood and that which is attributable to arterial blood.
- Pulse oximetry is used to determine arterial oxygen saturation, and the arterial oxygen saturation is, in turn, used to determine the venous oxygen saturation.
- FIG. 1 is a diagrammatic representation of a NIRS sensor placed on a subject's head.
- FIG. 2 is a diagrammatic representation of a NIRS sensor.
- FIG. 3 is a diagrammatic view of a NIRS sensor.
- FIG. 4 is a block diagram of the present methodology for calibrating a NIRS sensor.
- FIG. 5 is a graph showing an exemplary plot of absorption coefficient vs. wavelength.
- the present method of and apparatus for non-invasively determining the blood oxygen saturation level within a subject's tissue utilizes a near infrared spectrophotometric (NIRS) sensor that includes a transducer capable of transmitting a light signal into the tissue of a subject and sensing the light signal once it has passed through the tissue via transmittance or reflectance.
- NIRS near infrared spectrophotometric
- the present method and apparatus can be used with a variety of NIRS sensors.
- the present method is not limited to use with this preferred NIRS sensor, however.
- the preferred NIRS sensor includes a transducer portion 10 and processor portion 12 .
- the transducer portion 10 includes an assembly housing 14 and a connector housing 16 .
- the assembly housing 14 which is a flexible structure that can be attached directly to a subject's body, includes one or more light sources 18 and a light detector 20 .
- a disposable adhesive envelope or pad is used for mounting the assembly housing 14 easily and securely to the subject's skin.
- Light signals of known but different wavelengths from the light sources 18 emit through a prism assembly 22 .
- the light sources 18 are preferably laser diodes that emit light at a narrow spectral bandwidth at predetermined wavelengths. In one embodiment, the laser diodes are mounted within the connector housing 16 .
- the laser diodes are optically interfaced with a fiber optic light guide to the prism assembly 22 that is disposed within the assembly housing 14 .
- the light sources 18 are mounted within the assembly housing 14 .
- a first connector cable 26 connects the assembly housing 14 to the connector housing 16 and a second connector cable 28 connects the connector housing 16 to the processor portion 12 .
- the light detector 20 includes one or more photodiodes. The photodiodes are also operably connected to the processor portion 12 via the first and second connector cables 26 , 28 .
- the processor portion 12 includes a processor for processing light intensity signals from the light sources 18 and the light detector 20 .
- the processor utilizes an algorithm that characterizes a change in attenuation as a function of the difference in attenuation between different wavelengths.
- the present method advantageously accounts for but minimizes the attenuation effects of the scattering variable “G”, pathlength B*d, and the absorption “F” due to other components present in biological tissue (i.e. bone, water, skin pigmentation, etc.) that have a relatively flat or very low absorption spectra over the measured wavelength range.
- the present method accounts for any offset attenuation “N” due to the characteristics of the sensor that may or may not be wavelength independent.
- the present method algorithm can be expressed as:
- Equation 6 Equation 6
- Equation 6 Substituting Equation 6 into Equation 5 for A ⁇ 1 and A ⁇ 2 , the terms “F” and “N” within Equation 5 are subtracted out, provided they represent constant light absorption over the measurement wavelengths and provided the same sensor is used to sense the light signal at the various wavelengths. Therefore, in the case where the differential pathlength factor B is wavelength independent, then ⁇ A ⁇ 2 can be expressed as:
- ⁇ A ⁇ 12 ( ⁇ Hb ⁇ 1 ⁇ Hb ⁇ 2 )[ Hb]dB +( ⁇ HbO 2 ⁇ 1 ⁇ HbO 2 ⁇ 2 )[ HbO 2 ]dB+ ⁇ G ⁇ 12 (8)
- the differential pathlength factor “B” may be wavelength dependent. In this case, it is desirable to separate B ⁇ into two components:
- the parameter B is determined at one specific wavelength and the parameter k ⁇ represents how B would change at other wavelengths. To continue with the mathematical derivations, it is then desirable to combine the pathlength wavelength dependent parameter k ⁇ to ⁇ ⁇ :
- Equation 7 The parameter ⁇ ′ ⁇ represents the absorption coefficient ⁇ ⁇ adjusted by pathlength wavelength dependent parameter k ⁇ . Incorporation of these modifications into Equation 7 results in the following:
- ⁇ A ⁇ 12 ( ⁇ ′ Hb ⁇ 1 ⁇ a′ Hb ⁇ 2 )[ Hb]dB +( ⁇ ′ HbO 2 ⁇ 1 ⁇ ′ HbO 2 ⁇ 2 )[ HbO 2]dB+ ⁇ G ⁇ 12 (11)
- [0047] represents the attenuation attributable to HbO 2 ;
- [0048] represents the attenuation attributable to light scattering within tissue (G).
- the light absorption due to the fixed tissue absorbers (F), and sensor variability (N) may not be constant over the measuring wavelengths.
- differential attenuation as a function of wavelength would result in the parameters ⁇ F ⁇ 12 and ⁇ N ⁇ 12 , to be included in Equation 7 or Equation 11.
- ⁇ A ⁇ 12 ( ⁇ ′ Hb ⁇ 1 ⁇ ′ Hb ⁇ 2 )[ Hb]dB +( ⁇ ′ HbO 2 ⁇ 1 ⁇ ′ HbO 2 ⁇ 2 )[ HbO 2]dB+ ⁇ G ⁇ 12 + ⁇ F ⁇ 12 + ⁇ N ⁇ 12 (12)
- the parameter ⁇ N ⁇ 12 does not change in magnitude for a particular NIRS sensor.
- the parameter ⁇ F ⁇ 12 by definition, would be the result of differential attenuation due to components that have a relatively flat or very low absorption spectra over the measured wavelength range, and therefore would be a very small and relatively constant value when compared to the differential attenuation due to hemoglobin.
- ⁇ F ⁇ 12 can be seen as a fixed absorber error correcting parameter in Equation 12. Therefore, these parameters then can be summed together by superposition to become ⁇ G′ ⁇ 12 :
- ⁇ A ⁇ 12 ( ⁇ ′ Hb ⁇ 1 ⁇ ′ Hb ⁇ 2 )[ Hb]dB+ ( ⁇ ′ HbO 2 ⁇ 1 ⁇ ′ HbO 2 ⁇ 2 )[ HbO 2 ]dB+ ⁇ G′ ⁇ 12 (14)
- Equation 11 the effect of G is minimized within Equation 11, in contrast with the effect of G within Equation 2, at the cost of utilizing one more wavelength to determine Hb and HbO 2 .
- ⁇ G ⁇ 12 minimizes the effects of light attenuation due to scattering within tissue (G), fixed tissue absorbers (F), and sensor variability (N), at the same cost of utilizing one more wavelength.
- the value for CrSO 2 is initially determined from SmvO 2 using Equation 4 and the empirically determined values for SvO 2 and SaO 2 .
- the empirically determined values for SvO 2 and SaO 2 are based on data developed by discrete sampling or continuous monitoring of the subject's blood performed at or about the same time as the sensing of the tissue with the sensor. The temporal proximity of the NIRS sensing and the development of the empirical data helps assure accuracy.
- the initial values for Kv and Ka within Equation 4 are clinically reasonable values for the circumstances at hand.
- the values for A HbO2 and A Hb are determined mathematically using the values for Io ⁇ and I ⁇ for each wavelength sensed with the NIRS sensor (e.g., using Equation 2 or 6).
- the calibration parameters ⁇ Hb and ⁇ HbO2 which account for the effects of light attenuation due to scattering within tissue (G), fixed tissue absorbers (F), and measuring apparatus variability (N), are then determined using Equation 18 and non-linear regression techniques by correlation to different weighted values of SvO 2 and SaO 2 ; i.e., different values of Ka and Kv.
- Statistically acceptable values of Kv and Ka and ⁇ Hb and ⁇ HbO2 are converged upon using the non-linear regression techniques.
- Experimental findings show that after proper selection of Ka and Kv, the calibration parameters ⁇ Hb and ⁇ HbO2 are constant within a statistically acceptable margin of error for an individual NIRS sensor used to monitor brain oxygenation on different human subjects. In other words, once the sensor is calibrated it can be used on various human subjects and produce accurate information for each human subject.
- the photon pathlength “d*B” cancels out. If, however, the photon pathlength is known or estimated, then the determination of the total value of Hb and/or HbO 2 is possible. For example, if a value for pathlength “d*B” is input into Equation 17 along with the calibration values Hb and ⁇ HbO2 , then the total value of Hb and/or HbO 2 can be calculated.
- the light source to detector separation (optode) distance parameter “d” in the pathlength calculation is a measurable value and can be made constant by setting a fixed distance between light source to detector in the NIRS sensor design.
- the parameter “d” can be measured once the optodes are placed on the subject by use of calipers, ruler, or other distance measurement means.
- the pathlength differential factor “B” is more difficult to measure and requires more sophisticated equipment. From a large data set of measured neonatal and adult head differential pathlength factor values, an estimation of the value of “B” can be determined within a statistically acceptable margin of error. Substitution of these predetermined values of “B” into Equation 17 results in the determination of the total values of Hb and HbO 2 .
- Equation 3 An alternative method of determining total values of Hb and HbO 2 combines Equation 3 and Equation 17 together.
- ⁇ Hb and ⁇ HbO2 are determined using the above-described methodology for an individual NIRS sensor, this particular sensor is said to be calibrated.
- a calibrated NIRS sensor affords accurate measurement of total tissue oxygen saturation, CrSO 2 , by non-invasive means.
- the calibrated sensor can be used thereafter on any human patient, including adults and neonates.
- the present method is described above in terms of sensing blood oxygenation within cerebral tissue, the present method and apparatus are not limited to cerebral applications and can be used to determine blood oxygenation within tissue found elsewhere within the subject's body.
- the above-described method can also be used to establish a calibrated “reference” sensor that can be used to calibrate similar sensors through the use of a phantom sample (also referred to as a “reference sample”).
- the phantom sample has optical characteristics that are similar to the tissue being examined by the NIRS sensor.
- the calibrated reference NIRS sensor is used to sense the phantom sample and produce reference values.
- Similar, but uncalibrated, NIRS sensors can thereafter be calibrated by sensing the same phantom sample and adjusting either the hardware of the uncalibrated sensor or the output of the uncalibrated sensor until the output of the uncalibrated sensor agrees with the reference values produced by the calibrated reference sensor.
- the calibration parameters ⁇ Hb and ⁇ HbO2 for the uncalibrated sensor would be determined from the phantom sample. This technique makes it unnecessary to calibrate each new sensor in the manner described above, and thereby provides a relatively quick and cost effective way to calibrate NIRS sensors.
- Hb and HbO 2 Besides Hb and HbO 2 , other biological constituents of interest (e.g., cytochrome aa 3 , etc.) could be determined using the multivariate forms of equations 2, 3, 6 or 7. For each additional constituent to be determined, an additional measuring wavelength will be needed.
- biological constituents of interest e.g., cytochrome aa 3 , etc.
- the above-described methodology can be combined with pulse oximetry techniques to provide an alternative non-invasive method of distinguishing between oxygen saturation attributable to venous blood and that attributable to arterial blood.
- SmvO 2 is determined by the ratio of venous oxygen saturation SvO 2 and arterial oxygen saturation SaO 2 .
- a calibrated NIRS sensor affords accurate measurement of total tissue oxygen saturation, CrSO 2 , by using regression techniques by correlation to mixed venous oxygen saturation SmvO 2 . Therefore, the following expression will result:
- Non-invasive pulse oximetry techniques can be used to determine the arterial oxygen saturation (SaO 2 ) of peripheral tissue (i.e. finger, ear, nose) by monitoring pulsatile optical attenuation changes of detected light induced by pulsatile arterial blood volume changes in the arteriolar vascular system.
- venous oxygen saturation SvO2 would be determined from internal jugular vein (SijvO 2 ), jugular bulb (SjbO 2 ), or sagittal sinus (SssO 2 ) and the parameters Ka and Kv would be empirically determined during the calibration of the NIRS sensor. Under most physiological conditions, SpO 2 is representative of brain arterial oxygen saturation SaO 2 . Therefore, depending on which venous saturation parameter was used to calibrate the NIRS sensor, this clinically important parameter (i.e., SijvO 2 , SjbO 2 , or SssO 2 ) can be determined by Equation 24 by non-invasive means.
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Abstract
Description
- This application claims the benefit of the filing date of U.S. Provisional Application Ser. No. 60/201,359, filed May 2, 2000.
- [0002] This invention was made with Government support under Contract No. 1R43NS39723-01 awarded by the Department of Health & Human Services. The Government has certain rights in the invention.
- 1. Technical Field
- This invention relates to methods for non-invasively determining biological tissue oxygenation in general, and to non-invasive methods utilizing near-infrared spectroscopy (NIRS) techniques in particular.
- 2. Background Information
- The molecule that carries the oxygen in the blood is hemoglobin. Oxygenated hemoglobin is called oxyhemoglobin (HbO2) and deoxygenated hemoglobin is deoxyhemoglobin (Hb). Total hemoglobin is the summation of the two states of hemoglobin (Total Hb=HbO2+Hb), and is proportional to relative blood volume changes, provided that the hematocrit or hemoglobin concentration of the blood is unchanged. The mammalian cardiovascular system consists of a blood pumping mechanism (the heart), a blood transportation system (blood vessels), and a blood oxygenation system (the lungs). Blood oxygenated by the lungs passes through the heart and is pumped into the arterial vascular system. Under normal conditions, oxygenated arterial blood consists predominately of HbO2. Large arterial blood vessels branch off into smaller branches called arterioles, which profuse throughout biological tissue. The arterioles branch off into capillaries, the smallest blood vessels. In the capillaries, oxygen carried by hemoglobin is transported to the cells in the tissue, resulting in the release of oxygen molecules (HbO2→Hb). Under normal conditions, only a fraction of the HbO2 molecules give up oxygen to the tissue, depending on the cellular metabolic need. The capillaries then combine together into venuoles, the beginning of the venous circulatory system. Venuoles then combine into larger blood vessels called veins. The veins further combine and return to the heart, and then venous blood is pumped to the lungs. In the lungs, deoxygenated hemoglobin Hb collects oxygen becoming HbO2 again and the circulatory process is repeated.
-
- In the arterial circulatory system under normal conditions, there is a high proportion of HbO2 to Hb, resulting in an arterial oxygen saturation (defined as SaO2 %) of 95-100%. After delivery of oxygen to tissue via the capillaries, the proportion of HbO2 to Hb decreases. Therefore, the measured oxygen saturation of venous blood (defined as SvO2 %) is lower and may be about 70%.
- One spectrophotometric method, called pulse oximetry, determines arterial oxygen saturation (SaO2) of peripheral tissue (i.e. finger, ear, nose) by monitoring pulsatile optical attenuation changes of detected light induced by pulsatile arterial blood volume changes in the arteriolar vascular system. The method of pulse oximetry requires pulsatile blood volume changes in order to make a measurement. Since venous blood is not pulsatile, pulse oximetry cannot provide any information about venous blood.
- Near-infrared spectroscopy (NIRS) is an optical spectrophotometric method of continually monitoring tissue oxygenation that does not require pulsatile blood volume to calculate parameters of clinical value. The NIRS method is based on the principle that light in the near-infrared range (700 to 1,000 nm) can pass easily through skin, bone and other tissues where it encounters hemoglobin located mainly within micro-circulation passages; e.g., capillaries, arterioles, and venuoles. Hemoglobin exposed to light in the near infra-red range has specific absorption spectra that varies depending on its oxidation state; i.e., oxyhemoglobin (HbO2) and deoxyhemoglobin (Hb) each act as a distinct chromophore. By using light sources that transmit near-infrared light at specific different wavelengths, and measuring changes in transmitted or reflected light attenuation, concentration changes of the oxyhemoglobin (HbO2) and deoxyhemoglobin (Hb) can be monitored. The ability to continually monitor cerebral oxygenation levels is particularly valuable for those patients subject to a condition in which oxygenation levels in the brain may be compromised, leading to brain damage or death.
- The apparatus used in NIRS analysis typically includes a plurality of light sources, one or more light detectors for detecting reflected or transmitted light, and a processor for processing signals that represent the light emanating from the light source and the light detected by the light detector. Light sources such as light emitting diodes (LEDs) or laser diodes that produce light emissions in the wavelength range of 700-1000 nm at an intensity below that which would damage the biological tissue being examined are typically used. A photodiode or other light source detector is used to detect light reflected from or passed through the tissue being examined. The processor takes the signals from the light sources and the light detector and analyzes those signals in terms of their intensity and wave properties.
- It is known that relative changes of the concentrations of HbO2 and Hb can be evaluated using apparatus similar to that described above, including a processor programmed to utilize a variant of the Beer-Lambert Law, which accounts for optical attenuation in a highly scattering medium like biological tissue. The modified Beer-Lambert Law can be expressed as:
- A λ=−log(I/I 0)λ=αλ *C*d*B λ +G (2)
- wherein “Aλ” represents the optical attenuation in tissue at a particular wavelength λ (units: optical density or OD); “Io” represents the incident light intensity (units: W/cm2); “I” represents the detected light intensity; “αλ” represents the wavelength dependent absorption coefficient of the chromophore (units: OD * cm−1 * μM−1); “C” represents the concentration of chromophore (units: μM); “d” represents the light source to detector (optode) separation distance (units: cm); “Bλ” represents the wavelength dependent light scattering differential pathlength factor (unitless); and “G” represents light attenuation due to scattering within tissue (units: OD).
- Absolute measurement of chromophore concentration (C) is very difficult because G is unknown or difficult to ascertain. However, over a reasonable measuring period of several hours to days, G can be considered to remain constant, thereby allowing for the measurement of relative changes of chromophore from a zero reference baseline. Thus, if time t1 marks the start of an optical measurement (i.e., a base line) and time t2 is an arbitrary point in time after t1, a change in attenuation (ΔA) between t1 and t2 can be calculated, and variables G and lo will cancel out providing that they remain constant.
- The change in chromophore concentration (ΔC=C(t2)−C(t1)) can be determined from the change in attenuation ΔA, for example using the following equation derived from the Beer-Lambert Law:
- ΔA=−log(I t2 /I t1)λ=αλ *ΔC*d*B λ (3)
- Presently known NIRS algorithms that are designed to calculate the relative change in concentration of more than one chromophore use a multivariate form of Equation 2 or 3. To distinguish between, and to compute relative changes in, oxyhemoglobin (ΔHbO2) and deoxyhemoglobin (ΔHb), a minimum of two different wavelengths are typically used. The concentration of the HbO2 and Hb within the examined tissue is determined in λmoles per liter of tissue (μM).
- The above-described NIRS approach to determining oxygen saturation levels is useful, but it is limited in that it only provides information regarding a change in the level of blood oxygen saturation within the tissue. It does not provide a means for determining the total level of blood oxygen saturation within the biological tissue.
- At present, information regarding the relative contributions of venous and arterial blood within tissue examined by NIRS is either arbitrarily chosen or is determined by invasive sampling of the blood as a process independent from the NIRS examination. For example, It has been estimated that NIRS examined brain tissue consists of blood comprising from about 60 to 80% venous to about 20 to 40% arterial blood. Blood samples from catheters placed in venous drainage sites such as the internal jugular vein, jugular bulb, or sagittal sinus-have been used to evaluate NIRS measurements. It has been estimated in animal studies that NIRS interrogated tissue consists of a mixed vascular bed with a venous-to-arterial ratio of about 2:1 as determined from multiple linear regression analysis of sagittal sinus oxygen saturation (SSSO2) and carotid artery oxygen saturation (SaO2) in comparison to NIRS measured ΔHb and ΔHbO2. An expression representing the mixed venous/arterial oxygen saturation (SmvO2) in NIRS examined tissue is shown by the equation:
- SmvO 2 =Kv*SvO 2 +Ka*SaO 2 (4)
- where “SvO2” represents venous oxygen saturation; “SaO2” represents arterial oxygen saturation; and Kv and Ka are the weighted venous and arterial contributions respectively, with Kv+Ka=1. The parameters Kv and Ka may have constant values, or they may be a function of SvO2 and SaO2. Determined oxygen saturation from the internal jugular vein (SijvO2), jugular bulb (SjbO2), or sagittal sinus (SssO2) can be used to represent SvO2. Therefore, the value of each term in Equation 4 is empirically determined, typically by discretely sampling or continuously monitoring and subsequently evaluating patient arterial and venous blood from tissue that the NIRS sensor is examining, and using regression analysis to determine the relative contributions of venous and arterial blood independent of the NIRS examination.
- What is needed, therefore, is a method for non-invasively determining the level of oxygen saturation within biological tissue that can determine the total oxygen saturation level rather than a change in level; a method that provides calibration means to account for light attenuation due to scattering within tissue (G); and a method that can non-invasively distinguish the contribution of oxygen saturation attributable to venous blood and that which is attributable to arterial blood.
- It is, therefore, an object of the present invention to provide a method for non-invasively determining the total level of blood oxygen saturation within biological tissue.
- It is a further object of the present invention to provide a method that provides calibration means to account for light attenuation due to scattering within tissue, light attenuation due to fixed tissue absorbers, and light attenuation due to variability between light measuring apparatuses.
- It is a still further object of the present invention to provide a method that can non-invasively distinguish between the contribution of oxygen saturation attributable to venous blood and that attributable to arterial blood.
- According to the present invention, a method and apparatus for non-invasively determining the blood oxygen saturation level within a subject's tissue is provided that utilizes a near infrared spectrophotometric (NIRS) sensor capable of transmitting a light signal into the tissue of a subject and sensing the light signal once it has passed through the tissue via transmittance or reflectance. The method includes the step of determining attenuation of the light signal as the sum of: (i) attenuation attributable to deoxyhemoglobin; (ii) attenuation attributable to oxyhemoglobin; and (iii) attenuation attributable to light scattering within the subject's tissue. The present method also makes it possible to account for attenuation attributable to fixed or constant light absorbing biological tissue components, and attenuation attributable to variable characteristics of the sensor. By determining differential attenuation as a function of wavelength, the attenuation attributable to tissue light scattering characteristics, fixed light absorbing components, and measuring apparatus characteristics are mathematically cancelled out or minimized relative to the attenuation attributable to deoxyhemoglobin, and attenuation attributable to oxyhemoglobin.
- In order to account for the resulting minimized differential attenuation attributable to tissue light scattering characteristics, fixed light absorbing components, and measuring apparatus characteristics, each of the parameters must be measured or calibrated out. Since direct measurement is difficult, calibration to empirically determined data combined with data developed using the NIRS sensor is performed by using regression techniques. The empirically determined data is collected at or about the same time the data is developed with the NIRS sensor. Once the calibration parameters associated with attenuation attributable to tissue light scattering characteristics, fixed light absorbing components, and measuring apparatus characteristics have been determined, the NIRS sensor can be calibrated.
- The calibrated sensor can then be used to accurately and non-invasively determine the total oxygen saturation level in the original subject tissue or other subject tissue. In addition, if the separation distance (“d”) between the light source to the light detector is known or is determinable, and if the value of “B”, which represents the wavelength dependent light scattering differential pathlength factor, is known, then the total amount of concentrations of deoxyhemoglobin (Hb) and oxyhemoglobin (HbO2) within the examined tissue can be determined using the present method and apparatus.
- The calibrated sensor can be used subsequently to calibrate similar sensors without having to invasively produce a blood sample. Hence, the present method and apparatus enables a non-invasive determination of the blood oxygen saturation level within tissue. For example, an operator can create reference values by sensing a light signal or other reference medium using the calibrated sensor. The operator can then calibrate an uncalibrated sensor by sensing the same light signal or reference medium, and subsequently adjusting the uncalibrated sensor into agreement with the calibrated sensor. Hence, once a reference sensor is created, other similar sensors can be calibrated without the need for invasive procedure.
- There are, therefore, several advantages provided by the present method and apparatus. Those advantages include: 1) a practical non-invasive method and apparatus for determining oxygen saturation within tissue that can be used to determine the total blood oxygen saturation within tissue as opposed to a change in blood oxygen saturation; 2) a calibration method that accounts for light attenuation due to scattering within tissue (G), fixed tissue absorbers (F), and measuring apparatus variability (N); and 3) a practical non-invasive method and apparatus for determining oxygen saturation within tissue that can distinguish between the contribution of oxygen saturation attributable to venous blood and that saturation attributable to arterial blood.
- In an alternative embodiment, aspects of the above-described methodology are combined with pulse oximetry techniques to provide a non-invasive method of distinguishing between blood oxygen saturation within tissue that is attributable to venous blood and that which is attributable to arterial blood. Pulse oximetry is used to determine arterial oxygen saturation, and the arterial oxygen saturation is, in turn, used to determine the venous oxygen saturation.
- These and other objects, features, and advantages of the present invention method and apparatus will become apparent in light of the detailed description of the invention provided below and the accompanying drawings. The methodology and apparatus described below constitute a preferred embodiment of the underlying invention and do not, therefore, constitute all aspects of the invention that will or may become apparent by one of skill in the art after consideration of the invention disclosed overall herein.
- FIG. 1 is a diagrammatic representation of a NIRS sensor placed on a subject's head.
- FIG. 2 is a diagrammatic representation of a NIRS sensor.
- FIG. 3 is a diagrammatic view of a NIRS sensor.
- FIG. 4 is a block diagram of the present methodology for calibrating a NIRS sensor.
- FIG. 5 is a graph showing an exemplary plot of absorption coefficient vs. wavelength.
- The present method of and apparatus for non-invasively determining the blood oxygen saturation level within a subject's tissue is provided that utilizes a near infrared spectrophotometric (NIRS) sensor that includes a transducer capable of transmitting a light signal into the tissue of a subject and sensing the light signal once it has passed through the tissue via transmittance or reflectance. The present method and apparatus can be used with a variety of NIRS sensors. The NIRS sensor described below, which is the subject of co-pending U.S. patent application Ser. No. 09/434,146 filed Nov. 4, 1999 commonly assigned with the present application, discloses a preferred NIRS sensor. The present method is not limited to use with this preferred NIRS sensor, however.
- Referring to FIGS.1-5, the preferred NIRS sensor includes a
transducer portion 10 andprocessor portion 12. Thetransducer portion 10 includes anassembly housing 14 and aconnector housing 16. Theassembly housing 14, which is a flexible structure that can be attached directly to a subject's body, includes one or morelight sources 18 and alight detector 20. A disposable adhesive envelope or pad is used for mounting theassembly housing 14 easily and securely to the subject's skin. Light signals of known but different wavelengths from thelight sources 18 emit through aprism assembly 22. Thelight sources 18 are preferably laser diodes that emit light at a narrow spectral bandwidth at predetermined wavelengths. In one embodiment, the laser diodes are mounted within theconnector housing 16. The laser diodes are optically interfaced with a fiber optic light guide to theprism assembly 22 that is disposed within theassembly housing 14. In a second embodiment, thelight sources 18 are mounted within theassembly housing 14. Afirst connector cable 26 connects theassembly housing 14 to theconnector housing 16 and asecond connector cable 28 connects theconnector housing 16 to theprocessor portion 12. Thelight detector 20 includes one or more photodiodes. The photodiodes are also operably connected to theprocessor portion 12 via the first andsecond connector cables processor portion 12 includes a processor for processing light intensity signals from thelight sources 18 and thelight detector 20. - The processor utilizes an algorithm that characterizes a change in attenuation as a function of the difference in attenuation between different wavelengths. The present method advantageously accounts for but minimizes the attenuation effects of the scattering variable “G”, pathlength B*d, and the absorption “F” due to other components present in biological tissue (i.e. bone, water, skin pigmentation, etc.) that have a relatively flat or very low absorption spectra over the measured wavelength range. In addition, the present method accounts for any offset attenuation “N” due to the characteristics of the sensor that may or may not be wavelength independent. The present method algorithm can be expressed as:
- A λ1 −A λ2 =ΔA λ1−λ2 =ΔA λ12 (5)
- where Aλ1 and Aλ2 are in the form of Equation 6 below which is a modified version of Equation 2 that accounts for attenuation due to “F” and “N”:
- A λ=−log(I/I o)λ=αλ *C*d*B λ +G+F+N (6)
- Substituting Equation 6 into Equation 5 for Aλ1 and Aλ2, the terms “F” and “N” within Equation 5 are subtracted out, provided they represent constant light absorption over the measurement wavelengths and provided the same sensor is used to sense the light signal at the various wavelengths. Therefore, in the case where the differential pathlength factor B is wavelength independent, then ΔAλ2 can be expressed as:
- ΔA λ12=log[(I λ1 /Io λ1)*(I λ2 /Io λ2)]=Δαcλ12 cdB+ΔG λ12 (7)
- and rewritten in expanded form:
- ΔA λ12=(αHbλ1−αHbλ2)[Hb]dB+(αHbO
2 λ1−αHbO2 λ2)[HbO 2 ]dB+ΔG λ12 (8) - Alternatively, the differential pathlength factor “B” may be wavelength dependent. In this case, it is desirable to separate Bλ into two components:
- B λ =B*k 80 (9)
- The parameter B is determined at one specific wavelength and the parameter kλ represents how B would change at other wavelengths. To continue with the mathematical derivations, it is then desirable to combine the pathlength wavelength dependent parameter kλ to αλ:
- α′λ=αλ *k λ (10)
- The parameter α′λ represents the absorption coefficient αλ adjusted by pathlength wavelength dependent parameter kλ. Incorporation of these modifications into Equation 7 results in the following:
- ΔA λ12=(α′Hbλ1−a′Hbλ2)[Hb]dB+(α′HbO
2 λ1−α′HbO2 λ2)[HbO 2]dB+ΔG λ12 (11) - where:
- (α′Hbλ1−α′Hbλ2)[Hb]dB
- represents the attenuation attributable to Hb;
- (α′HbO
2 λ1−α′HbO2 λ2)[HbO2]dB - represents the attenuation attributable to HbO2; and
- ΔGλ12
- represents the attenuation attributable to light scattering within tissue (G).
- In another alternative case, the light absorption due to the fixed tissue absorbers (F), and sensor variability (N) may not be constant over the measuring wavelengths. In this case, differential attenuation as a function of wavelength would result in the parameters ΔFλ12 and ΔNλ12, to be included in Equation 7 or Equation 11.
- ΔA λ12=(α′Hbλ1−α′Hbλ2)[Hb]dB+(α′HbO
2 λ1−α′HbO2 λ2)[HbO 2]dB+ΔG λ12 +ΔF λ12 +ΔN λ12 (12) - The parameter ΔNλ12, does not change in magnitude for a particular NIRS sensor. The parameter ΔFλ12, by definition, would be the result of differential attenuation due to components that have a relatively flat or very low absorption spectra over the measured wavelength range, and therefore would be a very small and relatively constant value when compared to the differential attenuation due to hemoglobin. Thus, ΔFλ12 can be seen as a fixed absorber error correcting parameter in
Equation 12. Therefore, these parameters then can be summed together by superposition to become ΔG′λ12: - ΔG′ λ12 =ΔG λ12 +ΔF λ12 +ΔN λ12 (13)
- Incorporation of these modifications into
Equation 12 results in the following: - ΔA λ12=(α′Hbλ1−α′Hbλ2)[Hb]dB+(α′HbO
2 λ1−α′HbO2 λ2)[HbO 2 ]dB+ΔG′ λ12 (14) - Note that if ΔGλ12<<Gλ1 and Gλ2, the effect of G is minimized within Equation 11, in contrast with the effect of G within Equation 2, at the cost of utilizing one more wavelength to determine Hb and HbO2. Thus, a minimum of three different wavelengths is needed to determine Hb and HbO2. Also in the alternative case, ΔGλ12 minimizes the effects of light attenuation due to scattering within tissue (G), fixed tissue absorbers (F), and sensor variability (N), at the same cost of utilizing one more wavelength.
-
-
-
-
- Note that the pathlength d*B cancels out in the manipulation from Equation 17 to
Equation 18. - The value for CrSO2 is initially determined from SmvO2 using Equation 4 and the empirically determined values for SvO2 and SaO2. The empirically determined values for SvO2 and SaO2 are based on data developed by discrete sampling or continuous monitoring of the subject's blood performed at or about the same time as the sensing of the tissue with the sensor. The temporal proximity of the NIRS sensing and the development of the empirical data helps assure accuracy. The initial values for Kv and Ka within Equation 4 are clinically reasonable values for the circumstances at hand. The values for AHbO2 and AHb are determined mathematically using the values for Ioλ and Iλ for each wavelength sensed with the NIRS sensor (e.g., using Equation 2 or 6). The calibration parameters ΨHb and ΨHbO2, which account for the effects of light attenuation due to scattering within tissue (G), fixed tissue absorbers (F), and measuring apparatus variability (N), are then determined using
Equation 18 and non-linear regression techniques by correlation to different weighted values of SvO2 and SaO2; i.e., different values of Ka and Kv. Statistically acceptable values of Kv and Ka and ΨHb and ΨHbO2 are converged upon using the non-linear regression techniques. Experimental findings show that after proper selection of Ka and Kv, the calibration parameters ΨHb and ΨHbO2 are constant within a statistically acceptable margin of error for an individual NIRS sensor used to monitor brain oxygenation on different human subjects. In other words, once the sensor is calibrated it can be used on various human subjects and produce accurate information for each human subject. - In the determination of the CrSO2 percentage, the photon pathlength “d*B” cancels out. If, however, the photon pathlength is known or estimated, then the determination of the total value of Hb and/or HbO2 is possible. For example, if a value for pathlength “d*B” is input into Equation 17 along with the calibration values Hb and ΨHbO2, then the total value of Hb and/or HbO2 can be calculated. The light source to detector separation (optode) distance parameter “d” in the pathlength calculation is a measurable value and can be made constant by setting a fixed distance between light source to detector in the NIRS sensor design. Alternatively, the parameter “d” can be measured once the optodes are placed on the subject by use of calipers, ruler, or other distance measurement means. The pathlength differential factor “B” is more difficult to measure and requires more sophisticated equipment. From a large data set of measured neonatal and adult head differential pathlength factor values, an estimation of the value of “B” can be determined within a statistically acceptable margin of error. Substitution of these predetermined values of “B” into Equation 17 results in the determination of the total values of Hb and HbO2.
-
- At time t=t1, the values of ΔHb and ΔHbO2 are zero. Applying Equation 17, and knowing the calibration values of ΨHb and ΨHbO2 at a predetermined differential pathlength factor “B” and optode separation “d”, the total absolute values of Hb and HbO2 are determined at time t=t1, which are represented by [Hb]t1 and [HbO2]t1 respectively. At time t=t2, the values of ΔHb and ΔHbO2 are then determined using Equation 19. The total values of Hb and HbO2 are then determined at time t=t2 using the following equations:
- [Hb] t2 =ΔHb(t 2)+[Hb] t1 (20)
- [HbO 2]t2 =ΔHbO 2(t 2)+[HbO 2]t1 (21)
-
Equations 20 and 21 are valid only if all the shared parameters in Equations 17 and 19 are exact. Reduced to practice, the advantage of combining Equations 17 and 19 result in improved signal to noise ratio (SNR) in the calculation of the total values for Hb and HbO2. Conversely, improved SNR in the calculation of CrSO2 is also obtained from the following expression: - After the calibration parameters ΨHb and ΨHbO2 are determined using the above-described methodology for an individual NIRS sensor, this particular sensor is said to be calibrated. A calibrated NIRS sensor affords accurate measurement of total tissue oxygen saturation, CrSO2, by non-invasive means. The calibrated sensor can be used thereafter on any human patient, including adults and neonates. Although the present method is described above in terms of sensing blood oxygenation within cerebral tissue, the present method and apparatus are not limited to cerebral applications and can be used to determine blood oxygenation within tissue found elsewhere within the subject's body.
- According to an additional aspect of the present invention, the above-described method can also be used to establish a calibrated “reference” sensor that can be used to calibrate similar sensors through the use of a phantom sample (also referred to as a “reference sample”). The phantom sample has optical characteristics that are similar to the tissue being examined by the NIRS sensor. The calibrated reference NIRS sensor is used to sense the phantom sample and produce reference values. Similar, but uncalibrated, NIRS sensors can thereafter be calibrated by sensing the same phantom sample and adjusting either the hardware of the uncalibrated sensor or the output of the uncalibrated sensor until the output of the uncalibrated sensor agrees with the reference values produced by the calibrated reference sensor. Therefore, the calibration parameters ΨHb and ΨHbO2 for the uncalibrated sensor would be determined from the phantom sample. This technique makes it unnecessary to calibrate each new sensor in the manner described above, and thereby provides a relatively quick and cost effective way to calibrate NIRS sensors.
- Besides Hb and HbO2, other biological constituents of interest (e.g., cytochrome aa3, etc.) could be determined using the multivariate forms of equations 2, 3, 6 or 7. For each additional constituent to be determined, an additional measuring wavelength will be needed.
- In an alternative embodiment, the above-described methodology can be combined with pulse oximetry techniques to provide an alternative non-invasive method of distinguishing between oxygen saturation attributable to venous blood and that attributable to arterial blood. As demonstrated by Equation 4, SmvO2 is determined by the ratio of venous oxygen saturation SvO2 and arterial oxygen saturation SaO2. A calibrated NIRS sensor affords accurate measurement of total tissue oxygen saturation, CrSO2, by using regression techniques by correlation to mixed venous oxygen saturation SmvO2. Therefore, the following expression will result:
- CrSO 2 =SmvO 2 =Kv*SvO 2 +Ka*SaO 2 (23)
-
- For the brain, venous oxygen saturation SvO2 would be determined from internal jugular vein (SijvO2), jugular bulb (SjbO2), or sagittal sinus (SssO2) and the parameters Ka and Kv would be empirically determined during the calibration of the NIRS sensor. Under most physiological conditions, SpO2 is representative of brain arterial oxygen saturation SaO2. Therefore, depending on which venous saturation parameter was used to calibrate the NIRS sensor, this clinically important parameter (i.e., SijvO2, SjbO2, or SssO2) can be determined by Equation 24 by non-invasive means.
- Since many changes and variations of the disclosed embodiment of the invention may be made without departing from the inventive concept, it is not intended to limit the invention otherwise than as required by the appended claims.
Claims (44)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/845,146 US6456862B2 (en) | 2000-05-02 | 2001-04-30 | Method for non-invasive spectrophotometric blood oxygenation monitoring |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20135900P | 2000-05-02 | 2000-05-02 | |
US09/845,146 US6456862B2 (en) | 2000-05-02 | 2001-04-30 | Method for non-invasive spectrophotometric blood oxygenation monitoring |
Publications (2)
Publication Number | Publication Date |
---|---|
US20010047128A1 true US20010047128A1 (en) | 2001-11-29 |
US6456862B2 US6456862B2 (en) | 2002-09-24 |
Family
ID=22745515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/845,146 Expired - Lifetime US6456862B2 (en) | 2000-05-02 | 2001-04-30 | Method for non-invasive spectrophotometric blood oxygenation monitoring |
Country Status (5)
Country | Link |
---|---|
US (1) | US6456862B2 (en) |
EP (1) | EP1259791B1 (en) |
JP (1) | JP2003532107A (en) |
AU (1) | AU2001259258A1 (en) |
WO (1) | WO2001084107A2 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040015060A1 (en) * | 2002-06-21 | 2004-01-22 | James Samsoondar | Measurement of body compounds |
EP1545298A2 (en) * | 2002-07-26 | 2005-06-29 | Cas Medical Systems, Inc. | Method for spectrophotometric blood oxygenation monitoring |
US20080208066A1 (en) * | 2007-02-28 | 2008-08-28 | Can Cinbis | Implantable tissue perfusion sensing system and method |
US7738935B1 (en) * | 2002-07-09 | 2010-06-15 | Pacesetter, Inc. | Methods and devices for reduction of motion-induced noise in pulse oximetry |
US20100317947A1 (en) * | 2009-06-10 | 2010-12-16 | Can Cinbis | Tissue Oxygenation Monitoring in Heart Failure |
US20120271130A1 (en) * | 2011-04-11 | 2012-10-25 | Cas Medical Systems, Inc. | Method and apparatus for determining an oxygen desaturation event |
US20130274573A1 (en) * | 2012-03-09 | 2013-10-17 | University Of Georgia Research Foundation, Inc. | Systems And Methods For Measuring Mitochondrial Capacity |
WO2015044336A1 (en) * | 2013-09-30 | 2015-04-02 | Apd Advanced Perfusion Diagnostics | Non-invasive measurement device and method for estimating local metabolic parameters |
EP2503935A4 (en) * | 2009-11-24 | 2015-11-04 | Cas Medical Systems Inc | Method for spectrophotometric blood oxygenation monitoring of organs in the body |
US9597025B2 (en) | 2013-06-13 | 2017-03-21 | Nihon Kohden Corporation | Biological signal measuring system and biological signal measuring apparatus |
CN108072623A (en) * | 2016-11-18 | 2018-05-25 | 天津邦纳科技有限公司 | A kind of method that content of sulfur dioxide chemical sensor and spectrometer mutually verify |
CN108072624A (en) * | 2016-11-18 | 2018-05-25 | 天津邦纳科技有限公司 | A kind of method that amount of nitrogen oxides chemical sensor and spectrometer mutually verify |
WO2018187510A1 (en) * | 2017-04-04 | 2018-10-11 | Cas Medical Systems, Inc. | Method and apparatus for non-invasively measuring circulatory hemoglobin |
US20200337600A1 (en) * | 2016-06-28 | 2020-10-29 | Christopher Slawinski | Sample position resolved noninvasive glucose concentration determination analyzer apparatus and method of use thereof |
WO2023016636A1 (en) * | 2021-08-11 | 2023-02-16 | Luciole Medical AG | Methods and apparatus for measuring absolute concentration values of components, blood flow and blood volume in a tissue |
Families Citing this family (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6018673A (en) | 1996-10-10 | 2000-01-25 | Nellcor Puritan Bennett Incorporated | Motion compatible sensor for non-invasive optical blood analysis |
US6675031B1 (en) | 1999-04-14 | 2004-01-06 | Mallinckrodt Inc. | Method and circuit for indicating quality and accuracy of physiological measurements |
IL138884A (en) | 2000-10-05 | 2006-07-05 | Conmed Corp | Pulse oximeter and a method of its operation |
IL155527A0 (en) * | 2000-10-25 | 2003-11-23 | Robarts John P Res Inst | Method and apparatus for calculating blood flow parameters |
IL145445A (en) | 2001-09-13 | 2006-12-31 | Conmed Corp | Signal processing method and device for signal-to-noise improvement |
US6748254B2 (en) | 2001-10-12 | 2004-06-08 | Nellcor Puritan Bennett Incorporated | Stacked adhesive optical sensor |
JP2003144439A (en) * | 2001-11-09 | 2003-05-20 | Japan Science & Technology Corp | Method and device for measuring intrauterine oxygen moving state using optical technique |
US6865407B2 (en) * | 2002-07-11 | 2005-03-08 | Optical Sensors, Inc. | Calibration technique for non-invasive medical devices |
ATE479343T1 (en) | 2002-10-01 | 2010-09-15 | Nellcor Puritan Bennett Inc | USE OF A HEADBAND FOR VOLTAGE DISPLAY AND SYSTEM OF OXYMETER AND HEADBAND |
US7190986B1 (en) | 2002-10-18 | 2007-03-13 | Nellcor Puritan Bennett Inc. | Non-adhesive oximeter sensor for sensitive skin |
US7047056B2 (en) * | 2003-06-25 | 2006-05-16 | Nellcor Puritan Bennett Incorporated | Hat-based oximeter sensor |
ES2436214T3 (en) | 2003-09-12 | 2013-12-27 | Or-Nim Medical Ltd. | Non-invasive optical monitoring of a region of interest |
US8412297B2 (en) | 2003-10-01 | 2013-04-02 | Covidien Lp | Forehead sensor placement |
US7277741B2 (en) * | 2004-03-09 | 2007-10-02 | Nellcor Puritan Bennett Incorporated | Pulse oximetry motion artifact rejection using near infrared absorption by water |
US7706853B2 (en) * | 2005-02-10 | 2010-04-27 | Terumo Cardiovascular Systems Corporation | Near infrared spectroscopy device with reusable portion |
WO2006097910A1 (en) | 2005-03-16 | 2006-09-21 | Or-Nim Medical Ltd. | Noninvasive measurements in a human body |
US7747301B2 (en) * | 2005-03-30 | 2010-06-29 | Skyline Biomedical, Inc. | Apparatus and method for non-invasive and minimally-invasive sensing of parameters relating to blood |
EP2708180B1 (en) | 2005-05-12 | 2018-10-24 | Cas Medical Systems, Inc. | Improved method for spectrophotometric blood oxygenation monitoring |
US7590439B2 (en) | 2005-08-08 | 2009-09-15 | Nellcor Puritan Bennett Llc | Bi-stable medical sensor and technique for using the same |
US7657295B2 (en) | 2005-08-08 | 2010-02-02 | Nellcor Puritan Bennett Llc | Medical sensor and technique for using the same |
US7657294B2 (en) | 2005-08-08 | 2010-02-02 | Nellcor Puritan Bennett Llc | Compliant diaphragm medical sensor and technique for using the same |
US20070060808A1 (en) | 2005-09-12 | 2007-03-15 | Carine Hoarau | Medical sensor for reducing motion artifacts and technique for using the same |
US7904130B2 (en) | 2005-09-29 | 2011-03-08 | Nellcor Puritan Bennett Llc | Medical sensor and technique for using the same |
US7899510B2 (en) | 2005-09-29 | 2011-03-01 | Nellcor Puritan Bennett Llc | Medical sensor and technique for using the same |
US7869850B2 (en) | 2005-09-29 | 2011-01-11 | Nellcor Puritan Bennett Llc | Medical sensor for reducing motion artifacts and technique for using the same |
US8092379B2 (en) | 2005-09-29 | 2012-01-10 | Nellcor Puritan Bennett Llc | Method and system for determining when to reposition a physiological sensor |
US7483731B2 (en) | 2005-09-30 | 2009-01-27 | Nellcor Puritan Bennett Llc | Medical sensor and technique for using the same |
US7555327B2 (en) | 2005-09-30 | 2009-06-30 | Nellcor Puritan Bennett Llc | Folding medical sensor and technique for using the same |
US8062221B2 (en) | 2005-09-30 | 2011-11-22 | Nellcor Puritan Bennett Llc | Sensor for tissue gas detection and technique for using the same |
US7486979B2 (en) | 2005-09-30 | 2009-02-03 | Nellcor Puritan Bennett Llc | Optically aligned pulse oximetry sensor and technique for using the same |
US7881762B2 (en) | 2005-09-30 | 2011-02-01 | Nellcor Puritan Bennett Llc | Clip-style medical sensor and technique for using the same |
US8233954B2 (en) | 2005-09-30 | 2012-07-31 | Nellcor Puritan Bennett Llc | Mucosal sensor for the assessment of tissue and blood constituents and technique for using the same |
WO2007048039A2 (en) * | 2005-10-21 | 2007-04-26 | Cas Medical Systems, Inc. | Method and apparatus for spectrophotometric based oximetry |
US8077312B2 (en) * | 2005-11-09 | 2011-12-13 | Cas Medical Systems, Inc. | Calibration device for a spectrophotometric system |
US8761851B2 (en) * | 2005-12-06 | 2014-06-24 | Cas Medical Systems, Inc. | Indicators for a spectrophotometric system |
US8073518B2 (en) | 2006-05-02 | 2011-12-06 | Nellcor Puritan Bennett Llc | Clip-style medical sensor and technique for using the same |
US8145288B2 (en) | 2006-08-22 | 2012-03-27 | Nellcor Puritan Bennett Llc | Medical sensor for reducing signal artifacts and technique for using the same |
US8219170B2 (en) | 2006-09-20 | 2012-07-10 | Nellcor Puritan Bennett Llc | System and method for practicing spectrophotometry using light emitting nanostructure devices |
US8175671B2 (en) | 2006-09-22 | 2012-05-08 | Nellcor Puritan Bennett Llc | Medical sensor for reducing signal artifacts and technique for using the same |
US8396527B2 (en) | 2006-09-22 | 2013-03-12 | Covidien Lp | Medical sensor for reducing signal artifacts and technique for using the same |
US8195264B2 (en) | 2006-09-22 | 2012-06-05 | Nellcor Puritan Bennett Llc | Medical sensor for reducing signal artifacts and technique for using the same |
US7869849B2 (en) | 2006-09-26 | 2011-01-11 | Nellcor Puritan Bennett Llc | Opaque, electrically nonconductive region on a medical sensor |
US7574245B2 (en) | 2006-09-27 | 2009-08-11 | Nellcor Puritan Bennett Llc | Flexible medical sensor enclosure |
US7796403B2 (en) | 2006-09-28 | 2010-09-14 | Nellcor Puritan Bennett Llc | Means for mechanical registration and mechanical-electrical coupling of a faraday shield to a photodetector and an electrical circuit |
US7890153B2 (en) | 2006-09-28 | 2011-02-15 | Nellcor Puritan Bennett Llc | System and method for mitigating interference in pulse oximetry |
US7684842B2 (en) | 2006-09-29 | 2010-03-23 | Nellcor Puritan Bennett Llc | System and method for preventing sensor misuse |
US7476131B2 (en) | 2006-09-29 | 2009-01-13 | Nellcor Puritan Bennett Llc | Device for reducing crosstalk |
US8175667B2 (en) | 2006-09-29 | 2012-05-08 | Nellcor Puritan Bennett Llc | Symmetric LED array for pulse oximetry |
US7680522B2 (en) | 2006-09-29 | 2010-03-16 | Nellcor Puritan Bennett Llc | Method and apparatus for detecting misapplied sensors |
US8068891B2 (en) | 2006-09-29 | 2011-11-29 | Nellcor Puritan Bennett Llc | Symmetric LED array for pulse oximetry |
WO2008118216A1 (en) * | 2006-11-14 | 2008-10-02 | Cas Medical Systems, Inc. | Apparatus for spectrophotometric based oximetry |
US20080200784A1 (en) | 2007-02-16 | 2008-08-21 | Xuefeng Cheng | Method and device for measuring parameters of cardiac function |
US8918153B2 (en) | 2007-02-16 | 2014-12-23 | Mespere Lifesciences Inc. | Method and device for measuring parameters of cardiac function |
JP4974711B2 (en) * | 2007-03-05 | 2012-07-11 | 富士フイルム株式会社 | Printing device |
US8265724B2 (en) | 2007-03-09 | 2012-09-11 | Nellcor Puritan Bennett Llc | Cancellation of light shunting |
US7894869B2 (en) | 2007-03-09 | 2011-02-22 | Nellcor Puritan Bennett Llc | Multiple configuration medical sensor and technique for using the same |
US8280469B2 (en) | 2007-03-09 | 2012-10-02 | Nellcor Puritan Bennett Llc | Method for detection of aberrant tissue spectra |
US7541602B2 (en) | 2007-06-04 | 2009-06-02 | Or-Nim Medical Ltd. | System and method for noninvasively monitoring conditions of a subject |
US8352004B2 (en) | 2007-12-21 | 2013-01-08 | Covidien Lp | Medical sensor and technique for using the same |
US8346328B2 (en) | 2007-12-21 | 2013-01-01 | Covidien Lp | Medical sensor and technique for using the same |
US8366613B2 (en) | 2007-12-26 | 2013-02-05 | Covidien Lp | LED drive circuit for pulse oximetry and method for using same |
US8577434B2 (en) | 2007-12-27 | 2013-11-05 | Covidien Lp | Coaxial LED light sources |
US8452364B2 (en) | 2007-12-28 | 2013-05-28 | Covidien LLP | System and method for attaching a sensor to a patient's skin |
US8442608B2 (en) | 2007-12-28 | 2013-05-14 | Covidien Lp | System and method for estimating physiological parameters by deconvolving artifacts |
US8092993B2 (en) | 2007-12-31 | 2012-01-10 | Nellcor Puritan Bennett Llc | Hydrogel thin film for use as a biosensor |
US8897850B2 (en) | 2007-12-31 | 2014-11-25 | Covidien Lp | Sensor with integrated living hinge and spring |
US8199007B2 (en) | 2007-12-31 | 2012-06-12 | Nellcor Puritan Bennett Llc | Flex circuit snap track for a biometric sensor |
US8070508B2 (en) | 2007-12-31 | 2011-12-06 | Nellcor Puritan Bennett Llc | Method and apparatus for aligning and securing a cable strain relief |
WO2009100423A1 (en) * | 2008-02-08 | 2009-08-13 | Cas Medical Systems, Inc. | Improved method for spectrophotometric blood oxygenation monitoring |
WO2009116029A2 (en) | 2008-03-17 | 2009-09-24 | Or-Nim Medical Ltd. | Apparatus for non invasive optical monitoring |
US8437822B2 (en) | 2008-03-28 | 2013-05-07 | Covidien Lp | System and method for estimating blood analyte concentration |
US8112375B2 (en) | 2008-03-31 | 2012-02-07 | Nellcor Puritan Bennett Llc | Wavelength selection and outlier detection in reduced rank linear models |
US7887345B2 (en) | 2008-06-30 | 2011-02-15 | Nellcor Puritan Bennett Llc | Single use connector for pulse oximetry sensors |
US7880884B2 (en) | 2008-06-30 | 2011-02-01 | Nellcor Puritan Bennett Llc | System and method for coating and shielding electronic sensor components |
US8071935B2 (en) | 2008-06-30 | 2011-12-06 | Nellcor Puritan Bennett Llc | Optical detector with an overmolded faraday shield |
US8336391B2 (en) | 2008-07-06 | 2012-12-25 | Or-Nim Medical Ltd. | Method and system for non-invasively monitoring fluid flow in a subject |
US9027412B2 (en) | 2008-07-06 | 2015-05-12 | Or-Nim Medical Ltd. | Method and system for non-invasively monitoring fluid flow in a subject |
US8364220B2 (en) | 2008-09-25 | 2013-01-29 | Covidien Lp | Medical sensor and technique for using the same |
US8417309B2 (en) | 2008-09-30 | 2013-04-09 | Covidien Lp | Medical sensor |
US8914088B2 (en) | 2008-09-30 | 2014-12-16 | Covidien Lp | Medical sensor and technique for using the same |
US8423112B2 (en) | 2008-09-30 | 2013-04-16 | Covidien Lp | Medical sensor and technique for using the same |
US8391942B2 (en) * | 2008-10-06 | 2013-03-05 | Cas Medical Systems, Inc. | Method and apparatus for determining cerebral desaturation in patients undergoing deep hypothermic circulatory arrest |
US20100105998A1 (en) * | 2008-10-28 | 2010-04-29 | Cas Medical Systems, Inc. | Method and apparatus for spectrophotometric based oximetry of spinal tissue |
US8452366B2 (en) | 2009-03-16 | 2013-05-28 | Covidien Lp | Medical monitoring device with flexible circuitry |
US8221319B2 (en) | 2009-03-25 | 2012-07-17 | Nellcor Puritan Bennett Llc | Medical device for assessing intravascular blood volume and technique for using the same |
US8509869B2 (en) | 2009-05-15 | 2013-08-13 | Covidien Lp | Method and apparatus for detecting and analyzing variations in a physiologic parameter |
US8634891B2 (en) | 2009-05-20 | 2014-01-21 | Covidien Lp | Method and system for self regulation of sensor component contact pressure |
US9010634B2 (en) | 2009-06-30 | 2015-04-21 | Covidien Lp | System and method for linking patient data to a patient and providing sensor quality assurance |
US8311601B2 (en) | 2009-06-30 | 2012-11-13 | Nellcor Puritan Bennett Llc | Reflectance and/or transmissive pulse oximeter |
US8505821B2 (en) | 2009-06-30 | 2013-08-13 | Covidien Lp | System and method for providing sensor quality assurance |
WO2011006159A1 (en) | 2009-07-10 | 2011-01-13 | Cas Medical Systems, Inc. | Method for spectrophotometric blood oxygenation monitoring of the lower gastrointesinal tract |
US8391941B2 (en) | 2009-07-17 | 2013-03-05 | Covidien Lp | System and method for memory switching for multiple configuration medical sensor |
US8417310B2 (en) | 2009-08-10 | 2013-04-09 | Covidien Lp | Digital switching in multi-site sensor |
US8428675B2 (en) | 2009-08-19 | 2013-04-23 | Covidien Lp | Nanofiber adhesives used in medical devices |
US20110237910A1 (en) * | 2010-03-23 | 2011-09-29 | Cas Medical Systems, Inc. | Stabilized multi-wavelength laser system for non-invasive spectrophotometric monitoring |
US8391943B2 (en) | 2010-03-31 | 2013-03-05 | Covidien Lp | Multi-wavelength photon density wave system using an optical switch |
US7884933B1 (en) | 2010-05-05 | 2011-02-08 | Revolutionary Business Concepts, Inc. | Apparatus and method for determining analyte concentrations |
US8897848B2 (en) * | 2010-09-08 | 2014-11-25 | Cas Medical Systems, Inc. | Apparatus and method for non-invasively determining oxygen saturation of venous blood and cardiac output using NIRS |
US8649838B2 (en) | 2010-09-22 | 2014-02-11 | Covidien Lp | Wavelength switching for pulse oximetry |
US9775545B2 (en) | 2010-09-28 | 2017-10-03 | Masimo Corporation | Magnetic electrical connector for patient monitors |
WO2012050847A2 (en) | 2010-09-28 | 2012-04-19 | Masimo Corporation | Depth of consciousness monitor including oximeter |
CN103429153A (en) | 2010-11-03 | 2013-12-04 | 华盛顿大学商业中心 | Determination of tissue oxygenation in vivo |
EP2672893B1 (en) | 2011-02-13 | 2021-03-31 | Edwards Lifesciences Corporation | Nirs sensor assembly including electrically conductive and optically transparent emi shielding |
US9049893B2 (en) | 2011-02-25 | 2015-06-09 | Covidien Lp | Device for securing a medical sensor |
US20130030267A1 (en) * | 2011-07-29 | 2013-01-31 | Nellcor Puritan Bennett Llc | Multi-purpose sensor system |
JP6174592B2 (en) * | 2011-10-21 | 2017-08-02 | ノニン・メディカル・インコーポレーテッド | Age calibration for tissue oximetry |
US9913601B2 (en) | 2012-02-03 | 2018-03-13 | Cas Medical Systems, Inc. | Method and apparatus for monitoring a blood oxygen saturation level relative to a saturation threshold value |
US9907494B2 (en) | 2012-04-18 | 2018-03-06 | Hutchinson Technology Incorporated | NIRS device with optical wavelength and path length correction |
EP2928371B1 (en) * | 2012-12-10 | 2021-06-02 | Edwards Lifesciences Corporation | Method for spectrophotometrically determining a blood oxygen parameter |
US10398364B2 (en) | 2013-02-13 | 2019-09-03 | Mespere Lifesciences Inc. | Method and device for measuring venous blood oxygenation |
US9888422B2 (en) | 2013-06-03 | 2018-02-06 | Avago Technologies General Ip (Singapore) Pte. Ltd. | System and method for adaptive access and handover configuration based on prior history in a multi-RAT environment |
US9907006B2 (en) | 2013-06-03 | 2018-02-27 | Avago Technologies General Ip (Singapore) Pte. Ltd. | Cross radio access technology access with handoff and interference management using communication performance data |
US9848808B2 (en) | 2013-07-18 | 2017-12-26 | Cas Medical Systems, Inc. | Method for spectrophotometric blood oxygenation monitoring |
CN103610468A (en) * | 2013-12-05 | 2014-03-05 | 深圳市奥博莱特科技有限公司 | Blood oxygen blood volume absolute amount detection device and method thereof |
USD763939S1 (en) | 2014-04-02 | 2016-08-16 | Cephalogics, LLC | Optical sensor array liner with optical sensor array pad |
USD763938S1 (en) | 2014-04-02 | 2016-08-16 | Cephalogics, LLC | Optical sensor array |
US10154815B2 (en) | 2014-10-07 | 2018-12-18 | Masimo Corporation | Modular physiological sensors |
CN106562776A (en) | 2015-10-08 | 2017-04-19 | 米斯比尔生命科学公司 | System for non-invasive monitoring of central venous pressure |
CN105628481B (en) * | 2015-12-03 | 2018-05-29 | 浙江大学 | A kind of tissue oxygen detection calibration titer configuration device and calibration method |
FR3046048B1 (en) * | 2015-12-23 | 2020-03-27 | Bioserenity | DEVICE AND METHOD FOR MEASURING THE CONCENTRATION OF A BLOOD COMPOUND |
EP3360464A1 (en) | 2017-02-10 | 2018-08-15 | Carag AG | Apparatus and method for measuring the blood oxygen saturation in a subject's tissue |
WO2019126484A1 (en) | 2017-12-20 | 2019-06-27 | Cas Medical Systems, Inc. | Autoregulation system and method using tissue oximetry and blood pressure |
JP2024516239A (en) | 2021-04-28 | 2024-04-12 | エドワーズ ライフサイエンシーズ コーポレイション | Systems and methods for self-regulating data determination - Patents.com |
CA3218232A1 (en) | 2021-05-18 | 2022-11-24 | Edwards Lifesciences Corporation | Autoregulation system and method using tissue oximetry and blood pressure |
WO2023283171A1 (en) | 2021-07-06 | 2023-01-12 | Edwards Lifesciences Corporation | Method and apparatus for non-invasively measuring blood circulatory hemoglobin accounting for hemodynamic confounders |
EP4278951A1 (en) | 2022-05-16 | 2023-11-22 | Carag Ag | Spectrophotometric device for measuring blood oxygen saturation |
WO2024030547A1 (en) | 2022-08-05 | 2024-02-08 | Edwards Lifesciences Corporation | Method and system for predicting a limit to a subject's autoregulation range |
WO2024030548A1 (en) | 2022-08-05 | 2024-02-08 | Edwards Lifesciences Corporation | System and method for accounting for a confounding factor in the determination of a physiologic parameter or condition |
WO2024072871A1 (en) | 2022-09-27 | 2024-04-04 | Edwards Lifesciences Corporation | Method and apparatus for non-invasively measuring blood circulatory hemoglobin |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4105021A (en) | 1976-08-13 | 1978-08-08 | Joseph H. Allen | Method and arrangement for measuring blood pressure |
US4206764A (en) | 1976-12-08 | 1980-06-10 | Weisman & Allen | Method and apparatus for analyzing cardiovascular systems |
US4281645A (en) | 1977-06-28 | 1981-08-04 | Duke University, Inc. | Method and apparatus for monitoring metabolism in body organs |
US4321830A (en) | 1979-12-10 | 1982-03-30 | Optsonic Research Associates, Inc. | Optical bichromatic position finder |
US4770179A (en) | 1982-09-02 | 1988-09-13 | Nellcor Incorporated | Calibrated optical oximeter probe |
US4621643A (en) | 1982-09-02 | 1986-11-11 | Nellcor Incorporated | Calibrated optical oximeter probe |
US4700708A (en) | 1982-09-02 | 1987-10-20 | Nellcor Incorporated | Calibrated optical oximeter probe |
US4510838A (en) | 1983-06-06 | 1985-04-16 | Keith Alexis | Cymbal stand with rotating head |
US5217013A (en) | 1983-10-14 | 1993-06-08 | Somanetics Corporation | Patient sensor for optical cerebral oximeter and the like |
US4690492A (en) | 1984-09-04 | 1987-09-01 | Oximetrix, Inc. | Optical coupling |
US4913150A (en) | 1986-08-18 | 1990-04-03 | Physio-Control Corporation | Method and apparatus for the automatic calibration of signals employed in oximetry |
JPS6365845A (en) | 1986-09-05 | 1988-03-24 | ミノルタ株式会社 | Oximeter apparatus |
US4865038A (en) | 1986-10-09 | 1989-09-12 | Novametrix Medical Systems, Inc. | Sensor appliance for non-invasive monitoring |
US4907876A (en) | 1987-05-08 | 1990-03-13 | Hamamatsu Photonics Kabushiki Kaisha | Examination apparatus for measuring oxygenation in body organs |
US4805623A (en) * | 1987-09-04 | 1989-02-21 | Vander Corporation | Spectrophotometric method for quantitatively determining the concentration of a dilute component in a light- or other radiation-scattering environment |
US4848901A (en) | 1987-10-08 | 1989-07-18 | Critikon, Inc. | Pulse oximeter sensor control system |
JPH0628655B2 (en) * | 1988-09-30 | 1994-04-20 | 株式会社島津製作所 | Oxygen saturation measuring device |
US5119815A (en) * | 1988-12-21 | 1992-06-09 | Nim, Incorporated | Apparatus for determining the concentration of a tissue pigment of known absorbance, in vivo, using the decay characteristics of scintered electromagnetic radiation |
US5782755A (en) | 1993-11-15 | 1998-07-21 | Non-Invasive Technology, Inc. | Monitoring one or more solutes in a biological system using optical techniques |
US5902235A (en) * | 1989-03-29 | 1999-05-11 | Somanetics Corporation | Optical cerebral oximeter |
DE3912993C2 (en) | 1989-04-20 | 1998-01-29 | Nicolay Gmbh | Optoelectronic sensor for generating electrical signals based on physiological values |
CA2025330C (en) * | 1989-09-18 | 2002-01-22 | David W. Osten | Characterizing biological matter in a dynamic condition using near infrared spectroscopy |
US5058588A (en) | 1989-09-19 | 1991-10-22 | Hewlett-Packard Company | Oximeter and medical sensor therefor |
US5080098A (en) | 1989-12-18 | 1992-01-14 | Sentinel Monitoring, Inc. | Non-invasive sensor |
JPH04106748U (en) | 1991-02-28 | 1992-09-14 | 株式会社島津製作所 | Optical biomeasuring device |
WO1994012096A1 (en) | 1992-12-01 | 1994-06-09 | Somanetics Corporation | Patient sensor for optical cerebral oximeters |
US5520177A (en) | 1993-03-26 | 1996-05-28 | Nihon Kohden Corporation | Oximeter probe |
EP0699047A4 (en) | 1993-05-20 | 1998-06-24 | Somanetics Corp | Improved electro-optical sensor for spectrophotometric medical devices |
WO1994027493A1 (en) | 1993-05-28 | 1994-12-08 | Somanetics Corporation | Method and apparatus for spectrophotometric cerebral oximetry |
US5632273A (en) | 1994-02-04 | 1997-05-27 | Hamamatsu Photonics K.K. | Method and means for measurement of biochemical components |
US5421329A (en) | 1994-04-01 | 1995-06-06 | Nellcor, Inc. | Pulse oximeter sensor optimized for low saturation |
DE4417639A1 (en) | 1994-05-19 | 1995-11-23 | Boehringer Mannheim Gmbh | Analysis of concns. of substances in a biological sample |
US5697367A (en) | 1994-10-14 | 1997-12-16 | Somanetics Corporation | Specially grounded sensor for clinical spectrophotometric procedures |
US5758644A (en) | 1995-06-07 | 1998-06-02 | Masimo Corporation | Manual and automatic probe calibration |
GB9517366D0 (en) * | 1995-08-24 | 1995-10-25 | Johnson & Johnson Medical | Method of quantatively determining one or more characteristics of a substance |
US5752914A (en) | 1996-05-28 | 1998-05-19 | Nellcor Puritan Bennett Incorporated | Continuous mesh EMI shield for pulse oximetry sensor |
US5879294A (en) | 1996-06-28 | 1999-03-09 | Hutchinson Technology Inc. | Tissue chromophore measurement system |
-
2001
- 2001-04-30 JP JP2001581081A patent/JP2003532107A/en active Pending
- 2001-04-30 EP EP01932756.8A patent/EP1259791B1/en not_active Expired - Lifetime
- 2001-04-30 WO PCT/US2001/013875 patent/WO2001084107A2/en active Application Filing
- 2001-04-30 US US09/845,146 patent/US6456862B2/en not_active Expired - Lifetime
- 2001-04-30 AU AU2001259258A patent/AU2001259258A1/en not_active Abandoned
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7343185B2 (en) * | 2002-06-21 | 2008-03-11 | Nir Diagnostics Inc. | Measurement of body compounds |
US20040015060A1 (en) * | 2002-06-21 | 2004-01-22 | James Samsoondar | Measurement of body compounds |
US7738935B1 (en) * | 2002-07-09 | 2010-06-15 | Pacesetter, Inc. | Methods and devices for reduction of motion-induced noise in pulse oximetry |
US8788004B2 (en) | 2002-07-26 | 2014-07-22 | Cas Medical Systems, Inc. | Method for spectrophotometric blood oxygenation monitoring |
EP1545298A2 (en) * | 2002-07-26 | 2005-06-29 | Cas Medical Systems, Inc. | Method for spectrophotometric blood oxygenation monitoring |
EP1545298A4 (en) * | 2002-07-26 | 2008-11-26 | Cas Medical Systems Inc | Method for spectrophotometric blood oxygenation monitoring |
US20060189861A1 (en) * | 2002-07-26 | 2006-08-24 | Cas Medical Systems, Inc. | Method for spectrophotometric blood oxygenation monitoring |
US8078250B2 (en) | 2002-07-26 | 2011-12-13 | Cas Medical Systems, Inc. | Method for spectrophotometric blood oxygenation monitoring |
US20080208020A1 (en) * | 2007-02-28 | 2008-08-28 | Can Cinbis | Implantable tissue perfusion sensing system and method |
US20080208066A1 (en) * | 2007-02-28 | 2008-08-28 | Can Cinbis | Implantable tissue perfusion sensing system and method |
US8170650B2 (en) * | 2007-02-28 | 2012-05-01 | Medtronic, Inc. | Implantable tissue perfusion sensing system and method |
US8886465B2 (en) | 2007-02-28 | 2014-11-11 | Medtronic, Inc. | Implantable tissue perfusion sensing system and method |
US9636059B2 (en) | 2007-02-28 | 2017-05-02 | Medtronic, Inc. | Implantable tissue perfusion sensing system and method |
US8515537B2 (en) * | 2009-06-10 | 2013-08-20 | Medtronic, Inc. | Tissue oxygenation monitoring in heart failure |
US20100317947A1 (en) * | 2009-06-10 | 2010-12-16 | Can Cinbis | Tissue Oxygenation Monitoring in Heart Failure |
US11363976B2 (en) | 2009-11-24 | 2022-06-21 | Edwards Lifesciences Corporation | Method for spectrophotometric blood oxygenation monitoring of organs in the body |
US10485462B2 (en) | 2009-11-24 | 2019-11-26 | Edwards Lifesciences Corporation | Method for spectrophotometric blood oxygenation monitoring of organs in the body |
EP2503935A4 (en) * | 2009-11-24 | 2015-11-04 | Cas Medical Systems Inc | Method for spectrophotometric blood oxygenation monitoring of organs in the body |
US9364175B2 (en) | 2009-11-24 | 2016-06-14 | Cas Medical Systems, Inc. | Method for spectrophotometric blood oxygenation monitoring of organs in the body |
US20120271130A1 (en) * | 2011-04-11 | 2012-10-25 | Cas Medical Systems, Inc. | Method and apparatus for determining an oxygen desaturation event |
US9706959B2 (en) * | 2012-03-09 | 2017-07-18 | University Of Georgia Research Foundation, Inc. | Systems and methods for measuring mitochondrial capacity |
US20130274573A1 (en) * | 2012-03-09 | 2013-10-17 | University Of Georgia Research Foundation, Inc. | Systems And Methods For Measuring Mitochondrial Capacity |
US9597025B2 (en) | 2013-06-13 | 2017-03-21 | Nihon Kohden Corporation | Biological signal measuring system and biological signal measuring apparatus |
FR3011170A1 (en) * | 2013-09-30 | 2015-04-03 | Apd Advanced Perfusion Diagnostics | NON-INVASIVE MEASUREMENT DEVICE AND METHOD FOR ESTIMATING LOCAL METABOLIC PARAMETERS |
WO2015044336A1 (en) * | 2013-09-30 | 2015-04-02 | Apd Advanced Perfusion Diagnostics | Non-invasive measurement device and method for estimating local metabolic parameters |
US10653347B2 (en) | 2013-09-30 | 2020-05-19 | Apd Advanced Perfusion Diagnostics | Non-invasive measurement device and method for estimating local metabolic parameters |
US20200337600A1 (en) * | 2016-06-28 | 2020-10-29 | Christopher Slawinski | Sample position resolved noninvasive glucose concentration determination analyzer apparatus and method of use thereof |
CN108072623A (en) * | 2016-11-18 | 2018-05-25 | 天津邦纳科技有限公司 | A kind of method that content of sulfur dioxide chemical sensor and spectrometer mutually verify |
CN108072624A (en) * | 2016-11-18 | 2018-05-25 | 天津邦纳科技有限公司 | A kind of method that amount of nitrogen oxides chemical sensor and spectrometer mutually verify |
WO2018187510A1 (en) * | 2017-04-04 | 2018-10-11 | Cas Medical Systems, Inc. | Method and apparatus for non-invasively measuring circulatory hemoglobin |
WO2023016636A1 (en) * | 2021-08-11 | 2023-02-16 | Luciole Medical AG | Methods and apparatus for measuring absolute concentration values of components, blood flow and blood volume in a tissue |
Also Published As
Publication number | Publication date |
---|---|
WO2001084107A3 (en) | 2002-08-15 |
JP2003532107A (en) | 2003-10-28 |
EP1259791B1 (en) | 2013-11-13 |
AU2001259258A1 (en) | 2001-11-12 |
US6456862B2 (en) | 2002-09-24 |
WO2001084107A2 (en) | 2001-11-08 |
EP1259791A4 (en) | 2007-05-02 |
EP1259791A2 (en) | 2002-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6456862B2 (en) | Method for non-invasive spectrophotometric blood oxygenation monitoring | |
US8078250B2 (en) | Method for spectrophotometric blood oxygenation monitoring | |
US10117610B2 (en) | Method for spectrophotometric blood oxygenation monitoring | |
US6594513B1 (en) | Method and apparatus for determining oxygen saturation of blood in body organs | |
US4805623A (en) | Spectrophotometric method for quantitatively determining the concentration of a dilute component in a light- or other radiation-scattering environment | |
US6842635B1 (en) | Optical device | |
Ferrari et al. | Noninvasive determination of hemoglobin saturation in dogs by derivative near-infrared spectroscopy | |
JPH11244267A (en) | Blood component concentration measuring device | |
US20110028812A1 (en) | Method for spectrophotometric blood oxygenation monitoring | |
US20240049996A1 (en) | Nirs / tissue oximetry based method to measure arterial blood oxygen saturation from pulsatile hemoglobin waveforms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction | ||
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:CAS MEDICAL SYSTEMS, INC.;REEL/FRAME:021050/0039 Effective date: 20030429 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
AS | Assignment |
Owner name: NEWALLIANCE BANK,CONNECTICUT Free format text: SECURITY AGREEMENT;ASSIGNOR:CAS MEDICAL SYSTEMS, INC.;REEL/FRAME:024128/0648 Effective date: 20100311 Owner name: NEWALLIANCE BANK, CONNECTICUT Free format text: SECURITY AGREEMENT;ASSIGNOR:CAS MEDICAL SYSTEMS, INC.;REEL/FRAME:024128/0648 Effective date: 20100311 |
|
AS | Assignment |
Owner name: CAS MEDICAL SYSTEMS, INC., CONNECTICUT Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:FIRST NIAGARA BANK, N.A. SUCCESSOR BY MERGER TO NEWALLIANCE BANK;REEL/FRAME:026525/0955 Effective date: 20110623 |
|
FEPP | Fee payment procedure |
Free format text: PAT HOLDER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: LTOS); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 12 |
|
AS | Assignment |
Owner name: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT, MA Free format text: SECURITY INTEREST;ASSIGNOR:CAS MEDICAL SYSTEMS, INC.;REEL/FRAME:033247/0323 Effective date: 20140627 |
|
AS | Assignment |
Owner name: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR Free format text: ASSIGNMENT OF INTELLECTUAL PROPERTY SECURITY AGREEMENT;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING AGENT;REEL/FRAME:037112/0159 Effective date: 20151113 |
|
AS | Assignment |
Owner name: SOLAR CAPITAL LTD., AS SUCCESSOR AGENT, NEW YORK Free format text: ASSIGNMENT OF INTELLECTUAL PROPERTY SECURITY AGREEMENT;ASSIGNOR:HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS RETIRING AGENT;REEL/FRAME:038711/0067 Effective date: 20160513 |
|
AS | Assignment |
Owner name: SOLAR CAPITAL LTD., NEW YORK Free format text: PATENT SECURITY AGREEMENT;ASSIGNOR:CAS MEDICAL SYSTEMS, INC.;REEL/FRAME:039221/0004 Effective date: 20160630 |
|
AS | Assignment |
Owner name: CAS MEDICAL SYSTEMS, INC., CONNECTICUT Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:SOLAR CAPITAL LTD.;REEL/FRAME:045823/0342 Effective date: 20180508 |
|
AS | Assignment |
Owner name: CAS MEDICAL SYSTEMS, INC., CONNECTICUT Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BENNI, PAUL;REEL/FRAME:047618/0705 Effective date: 20000424 |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
AS | Assignment |
Owner name: EDWARDS LIFESCIENCES CORPORATION, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CAS MEDICAL SYSTEMS, INC.;REEL/FRAME:050635/0654 Effective date: 20190923 |